Cases & Deals

  • Home
  • Practices
  • Merck develops global patent portfolio related to novel bispecific Tie2 agonist/VEGF inhibitor for treatment of retinal diseases

Share

Merck develops global patent portfolio related to novel bispecific Tie2 agonist/VEGF inhibitor for treatment of retinal diseases

October 2026

Client(s) Merck Sharpe & Dohme LLC

Jones Day is representing Merck Sharp & Dohme LLC in the development and prosecution of a global patent portfolio related to MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody with a dual mechanism that directly activates the Tie2 pathway and inhibits vascular endothelial growth factor (VEGF) with the goal of stabilizing retinal and choroidal blood vessels and reducing fluid accumulation in the macula. MK-8748 is currently in clinical trials for the treatment of neovascular (wet) age-related macular degeneration (NVAMD).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.